# Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review

## TL;DR

This paper reports a successful treatment of a rare composite lymphoma using Sintilimab and AVD, achieving partial remission and normal quality of life.

## Contribution

First successful use of a PD-1 inhibitor combined with AVD for composite Hodgkin and follicular lymphoma.

## Key findings

- The patient achieved partial remission after treatment with Sintilimab+AVD.
- The patient maintained a normal quality of life during and after treatment.
- This treatment approach shows potential for managing composite lymphoma subtypes.

## Abstract

Composite lymphoma has been rarely reported due to its low incidence. The treatment of composite lymphoma depends on the specific lymphoma subtypes involved. No standardized therapeutic regimen has been established. We tried to treat the patient with Sintilimab+AVD for composite Hodgkin lymphoma and follicular lymphoma, after which the patient was able to maintain a normal quality of life and achieved partial remission (PR). To the best of our knowledge, this is the first attempt to use the PD-1 inhibitor combined with the AVD regimen successfully for the treatment of composite Hodgkin lymphoma and follicular lymphoma.